Logo image
Se connecter
Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial (vol 29 , pg 2593, 2023)
Article de revue   Avec comité de lecture

Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial (vol 29 , pg 2593, 2023)

Roch Houot, Emmanuel Bachy, Guillaume Cartron, Francois-Xavier Gros, Franck Morschhauser, Lucie Oberic, Thomas Gastinne, Pierre Feugier, Remy Dulery, Catherine Thieblemont, …
Nature medicine, Vol.30(7), pp.2089-2089
01/07/2024
PMID: 38745012

Résumé

Biochemistry & Molecular Biology Cell Biology Life Sciences & Biomedicine Medicine, Research & Experimental Research & Experimental Medicine Science & Technology

Indicateurs

1 Consultations de la notice

Détails

Logo image